Amneal Pharmaceuticals (AMRX) Financials

$13.60 +0.20 (+1.45%)

Closing price 03:59 PM Eastern

Extended Trading

$13.62 +0.01 (+0.07%)

As of 04:10 PM Eastern

Annual Income Statements for Amneal Pharmaceuticals

This table shows Amneal Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	0.00	0.00	-21	-362	91	11	-130	-84	-117	72
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74	128
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74	128
Total Pre-Tax Income	215	171	-203	-220	-36	31	-248	-40	-55	139
Total Operating Income	285	245	-20	-249	91	153	-95	204	249	394
Total Gross Profit	597	526	716	353	628	769	785	821	1,020	1,113
Total Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794	3,019
Operating Revenue	1,018	1,034	1,663	1,626	1,993	2,094	2,212	2,394	2,794	3,019
Total Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774	1,905
Operating Cost of Revenue	421	507	947	1,273	1,364	1,325	1,428	1,573	1,774	1,905
Total Operating Expenses	313	281	736	602	537	616	880	616	771	719
Selling, General & Admin Expense	119	109	228	290	327	366	400	430	476	527
Research & Development Expense	179	171	194	188	180	202	200	168	197	194
Other Operating Expenses / (Income)	-	21	16	14	11	7.72	-5.87	-16	-0.93	-5.24
Impairment Charge	0.00	0.00	39	47	2.68	0.71	13	31	0.00	0.00
Restructuring Charge	0.07	9.40	278	51	11	15	2.13	1.75	2.36	4.21
Other Special Charges / (Income)	15	-29	-20	12	5.86	25	271	1.82	97	-0.39
Total Other Income / (Expense), net	-70	-74	-183	28	-127	-121	-153	-245	-304	-255
Interest Expense	0.00	2.53	20	-	0.00	0.00	0.29	41	0.00	31
Interest & Investment Income	-55	-71	-144	-168	-146	-136	-158	-211	-259	-241
Other Income / (Expense), net	-15	-0.19	-20	197	19	15	5.47	6.79	-46	18
Income Tax Expense	5.40	2.00	-1.42	383	-104	11	6.66	8.45	19	11
Net Income / (Loss) Attributable to Noncontrolling Interest	2.05	1.68	-33	-242	-22	9.55	-125	35	43	56
Basic Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)	$0.23
Weighted Average Basic Shares Outstanding	0.00	-	127.25M	132.11M	147.44M	148.92M	150.94M	176.14M	308.98M	313.37M
Diluted Earnings per Share	$0.00	-	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)	$0.22
Weighted Average Diluted Shares Outstanding	0.00	-	127.25M	132.11M	148.91M	151.82M	150.94M	176.14M	308.98M	324.81M
Weighted Average Basic & Diluted Shares Outstanding	0.00	-	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M	314.63M

This table shows Amneal Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	12	9.68	-99	-92	5.99	-0.16	-31	12	22	2.37	35
Consolidated Net Income / (Loss)	30	25	-93	-82	17	12	-21	25	36	18	50
Net Income / (Loss) Continuing Operations	30	25	-93	-82	17	12	-21	25	36	18	50
Total Pre-Tax Income	30	23	-83	-76	20	15	-15	37	52	-5.22	55
Total Operating Income	80	76	14	-11	95	89	76	100	111	70	112
Total Gross Profit	220	233	190	238	250	270	263	256	286	274	297
Total Revenue	599	620	617	659	702	702	731	695	725	785	814
Operating Revenue	599	620	617	659	702	702	731	695	725	785	814
Total Cost of Revenue	379	388	427	421	452	433	468	440	438	511	517
Operating Cost of Revenue	379	388	427	421	452	433	468	440	438	511	517
Total Operating Expenses	140	157	176	249	154	181	187	156	175	204	185
Selling, General & Admin Expense	106	113	109	113	116	119	129	118	124	138	146
Research & Development Expense	38	41	50	40	37	63	60	42	50	66	36
Other Operating Expenses / (Income)	0.83	0.96	-3.35	0.10	0.00	-1.03	-3.99	-5.12	0.00	-0.12	-0.00
Restructuring Charge	0.08	1.04	0.11	1.47	0.22	0.17	0.49	0.57	1.02	0.14	2.47
Total Other Income / (Expense), net	-50	-53	-98	-65	-75	-73	-91	-63	-60	-76	-57
Interest & Investment Income	-51	-51	-60	-66	-66	-66	-62	-57	-65	-63	-56
Other Income / (Expense), net	0.43	-1.78	2.70	0.93	-9.35	-7.88	-29	-5.92	5.44	19	-0.56
Income Tax Expense	0.00	-2.08	9.86	6.16	3.62	3.67	5.42	13	16	-23	5.66
Net Income / (Loss) Attributable to Noncontrolling Interest	18	15	5.31	9.97	11	12	10	12	13	16	14
Basic Earnings per Share	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.11
Weighted Average Basic Shares Outstanding	153.74M	154.22M	176.14M	307.28M	309.12M	309.65M	308.98M	311.05M	313.74M	314.17M	313.37M
Diluted Earnings per Share	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.10
Weighted Average Diluted Shares Outstanding	154.89M	159.69M	176.14M	307.28M	318.96M	309.65M	308.98M	323.96M	322.36M	324.75M	324.81M
Weighted Average Basic & Diluted Shares Outstanding	306.31M	306.54M	307.01M	308.65M	309.54M	309.84M	309.97M	313.42M	314.08M	314.36M	314.63M

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-29	41	141	-66	194	-90	-222	64	19	195
Net Cash From Operating Activities	115	234	250	1.71	379	242	65	346	295	340
Net Cash From Continuing Operating Activities	115	234	250	1.71	379	242	65	346	295	340
Net Income / (Loss) Continuing Operations	209	169	-201	-604	69	20	-255	-49	-74	128
Consolidated Net Income / (Loss)	209	169	-201	-604	69	20	-255	-49	-74	128
Depreciation Expense	33	46	137	207	235	233	240	229	236	224
Amortization Expense	3.00	4.59	16	43	8.68	9.20	8.60	12	29	22
Non-Cash Adjustments To Reconcile Net Income	26	23	294	109	129	115	133	225	162	172
Changes in Operating Assets and Liabilities, net	-156	-8.51	3.78	246	-63	-136	-62	-72	-59	-205
Net Cash From Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63	-112
Net Cash From Continuing Investing Activities	-125	-99	-396	-20	-318	-194	-174	-69	-63	-112
Purchase of Property, Plant & Equipment	-123	-95	-83	-47	-62	-51	-49	-47	-60	-99
Acquisitions	-1.85	-20	-339	-50	-256	-148	-127	-22	-15	-16
Sale of Property, Plant & Equipment	0.00	0.00	25	-	-	-	-	0.00	0.00	2.09
Divestitures	0.00	16	0.00	35	-	-	0.00	0.00	12	0.00
Net Cash From Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212	-32
Net Cash From Continuing Financing Activities	-19	-95	288	-46	132	-138	-107	-213	-212	-32
Repayment of Debt	-43	-19	-839	-27	-40	-79	-125	-576	-233	-2,886
Issuance of Debt	225	300	1,325	0.00	180	0.00	85	437	48	2,913
Other Financing Activities, net	-0.26	0.04	-3.76	-19	-4.92	-1.90	-47	-73	-27	-58
Effect of Exchange Rate Changes	-	-	-0.67	-2.25	1.04	0.10	-5.68	0.07	-1.00	-1.68
Cash Interest Paid	51	65	132	159	130	122	143	193	264	198
Cash Income Taxes Paid	4.92	-5.78	35	10	100	-16	13	2.50	15	21

This table details how cash moves in and out of Amneal Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
Net Change in Cash & Equivalents	-36	-19	3.50	-47	-2.00	29	40	-50	15	155	75
Net Cash From Operating Activities	-11	81	136	-4.41	40	142	118	7.41	84	118	130
Net Cash From Continuing Operating Activities	-11	81	136	-4.41	40	142	118	7.41	84	118	130
Net Income / (Loss) Continuing Operations	30	25	-93	-82	17	12	-21	25	36	18	50
Consolidated Net Income / (Loss)	30	25	-93	-82	17	12	-21	25	36	18	50
Depreciation Expense	57	57	57	56	56	59	66	60	60	54	49
Amortization Expense	2.47	2.36	4.66	6.80	0.93	1.44	26	6.81	6.88	5.03	3.72
Non-Cash Adjustments To Reconcile Net Income	27	30	133	32	27	39	59	21	23	90	38
Changes in Operating Assets and Liabilities, net	-128	-33	34	-17	-61	31	-12	-105	-42	-49	-10
Net Cash From Investing Activities	-12	-13	-32	-20	-6.47	-21	-16	-18	-27	-22	-45
Net Cash From Continuing Investing Activities	-12	-13	-32	-20	-6.47	-21	-16	-18	-27	-22	-45
Purchase of Property, Plant & Equipment	-11	-12	-12	-10	-11	-17	-22	-14	-27	-15	-43
Acquisitions	-1.15	-1.00	-20	-9.70	-0.75	-3.60	-0.60	-4.20	-0.90	-7.41	-3.00
Sale of Property, Plant & Equipment	-	-	-	0.00	-	-	-	0.52	0.86	-	0.72
Net Cash From Financing Activities	-12	-87	-101	-23	-35	-92	-61	-39	-42	59	-10
Net Cash From Continuing Financing Activities	-12	-87	-101	-23	-35	-92	-61	-39	-42	59	-10
Repayment of Debt	-15	-64	-424	-63	-27	-87	-56	-236	-17	-2,628	-6.12
Other Financing Activities, net	-0.01	0.22	-0.11	-7.18	0.20	0.42	-0.24	-22	-24	-7.77	-4.00
Effect of Exchange Rate Changes	-0.60	-0.30	0.20	-0.17	-0.10	0.01	-0.74	-0.47	-0.31	-0.69	-0.21
Cash Interest Paid	48	48	56	65	72	66	61	56	56	44	41
Cash Income Taxes Paid	0.50	-3.49	2.07	4.57	15	-1.15	6.16	3.61	8.95	5.01	3.75

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501	3,678
Total Current Assets	772	1,287	1,210	1,552	1,520	1,412	1,378	1,588	1,911
Cash & Equivalents	74	213	151	341	248	26	92	111	282
Restricted Cash	3.76	5.39	1.63	5.74	8.95	9.25	7.57	7.87	29
Accounts Receivable	368	482	606	640	664	742	615	776	896
Inventories, net	284	457	381	491	489	531	581	612	606
Prepaid Expenses	42	128	70	73	110	104	83	81	98
Plant, Property, & Equipment, net	487	544	478	478	514	470	448	425	443
Total Noncurrent Assets	83	2,522	2,109	1,977	1,905	1,918	1,647	1,489	1,324
Noncurrent Note & Lease Receivables	-	0.00	123	68	64	63	59	56	53
Goodwill	26	426	420	523	593	599	599	597	595
Intangible Assets	45	1,655	1,383	1,305	1,167	1,096	890	732	563
Other Noncurrent Operating Assets	11	68	184	81	81	159	99	102	112
Total Liabilities & Shareholders' Equity	1,342	4,353	3,666	4,006	3,940	3,799	3,473	3,501	3,678
Total Liabilities	1,717	3,456	3,319	3,649	3,556	3,590	3,411	3,546	3,672
Total Current Liabilities	297	554	550	677	677	753	847	1,130	882
Short-Term Debt	89	22	21	45	31	90	213	324	6.76
Accounts Payable	207	532	513	619	573	541	542	758	817
Other Current Liabilities	-	0.00	18	16	76	122	91	48	58
Total Noncurrent Liabilities	1,421	2,903	2,769	2,972	2,879	2,838	2,565	2,416	2,791
Long-Term Debt	1,355	2,631	2,609	2,772	2,718	2,592	2,427	2,162	2,565
Capital Lease Obligations	40	39	61	-	60	61	59	57	55
Asset Retirement Reserve & Litigation Obligation	-	-	-	-	-	-	0.32	85	72
Other Noncurrent Operating Liabilities	7.79	39	98	201	100	185	78	112	99
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	0.00	12	17	25	41	65	77
Total Equity & Noncontrolling Interests	-376	896	347	345	367	184	20	-110	-71
Total Preferred & Common Equity	-386	505	232	303	360	298	20	-109	-71
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-386	505	232	303	360	298	20	-109	-71
Common Stock	11	533	610	631	661	695	542	563	575
Retained Earnings	-383	-21	-378	-287	-276	-406	-490	-607	-535
Accumulated Other Comprehensive Income / (Loss)	-14	-7.76	-0.07	-41	-25	9.94	-32	-66	-111
Noncontrolling Interest	10	392	115	42	6.63	-114	0.23	-0.25	-0.54

This table presents Amneal Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025
Total Assets	3,874	3,627	3,701	3,687	3,456	3,510	3,461	3,365	3,423	3,600
Total Current Assets	1,420	1,307	1,422	1,456	1,380	1,485	1,513	1,510	1,585	1,838
Cash & Equivalents	87	145	109	87	47	44	74	59	72	201
Restricted Cash	8.56	6.40	-	-	-	-	-	-	-	35
Accounts Receivable	630	546	675	693	670	779	757	755	809	886
Inventories, net	544	529	551	576	571	576	596	601	609	615
Prepaid Expenses	150	81	82	91	87	82	82	89	85	102
Plant, Property, & Equipment, net	470	463	459	452	440	425	431	427	440	435
Total Noncurrent Assets	1,984	1,857	1,820	1,779	1,637	1,599	1,517	1,428	1,398	1,326
Noncurrent Note & Lease Receivables	64	62	62	61	60	58	58	56	55	54
Goodwill	600	599	599	599	599	599	598	597	597	596
Intangible Assets	1,159	1,055	1,015	983	859	820	780	689	650	588
Other Noncurrent Operating Assets	161	140	144	137	119	122	81	85	96	88
Total Liabilities & Shareholders' Equity	3,874	3,627	3,701	3,687	3,456	3,510	3,461	3,365	3,423	3,600
Total Liabilities	3,657	3,464	3,518	3,496	3,473	3,514	3,495	3,425	3,470	3,642
Total Current Liabilities	818	704	777	761	834	1,114	1,095	1,076	1,107	862
Short-Term Debt	90	130	150	107	213	436	365	322	321	7.20
Accounts Payable	535	482	534	561	576	632	684	695	730	800
Other Current Liabilities	193	92	90	90	43	44	47	59	56	55
Total Noncurrent Liabilities	2,839	2,761	2,741	2,735	2,639	2,400	2,399	2,349	2,362	2,780
Long-Term Debt	2,646	2,602	2,549	2,542	2,378	2,178	2,170	2,154	2,146	2,567
Capital Lease Obligations	61	60	-	-	-	-	-	-	-	56
Asset Retirement Reserve & Litigation Obligation	-	-	-	-	85	85	85	73	74	74
Other Noncurrent Operating Liabilities	132	99	191	193	175	137	144	122	142	83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	22	28	32	37	47	53	60	73	66	68
Total Equity & Noncontrolling Interests	194	135	151	154	-64	-57	-94	-132	-113	-110
Total Preferred & Common Equity	297	294	318	331	-64	-57	-93	-132	-112	-109
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	297	294	318	331	-64	-57	-93	-132	-112	-109
Common Stock	687	704	711	719	542	549	556	549	558	567
Retained Earnings	-402	-413	-401	-392	-582	-576	-576	-595	-572	-570
Accumulated Other Comprehensive Income / (Loss)	13	3.76	8.08	3.87	-24	-30	-74	-86	-97	-106
Noncontrolling Interest	-103	-160	-167	-177	0.10	-0.02	-0.14	-0.33	-0.42	-0.50

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	0.23
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	278	242	-14	-174	64	98	-66	143	175	362
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-2.27%	5.26%	7.17%	14.17%
Earnings before Interest and Taxes (EBIT)	270	245	-39	-52	110	168	-89	211	204	412
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	306	295	114	198	354	410	159	452	469	658
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-804	-2,336	180	256	-13	-49	398	456	420
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	1,046	3,369	3,015	2,823	2,933	2,916	2,661	2,380	2,322
Increase / (Decrease) in Invested Capital	0.00	1,046	2,323	-354	-192	111	-17	-255	-281	-58
Book Value per Share	$0.00	$0.00	$1.69	$0.78	$1.01	$1.20	$0.98	$0.06	($0.35)	($0.23)
Tangible Book Value per Share	$0.00	$0.00	($5.28)	($5.25)	($5.08)	($4.64)	($4.60)	($4.79)	($4.64)	($3.91)
Total Capital	0.00	1,109	3,588	3,039	3,174	3,193	2,952	2,760	2,498	2,633
Total Debt	0.00	1,485	2,691	2,692	2,817	2,809	2,743	2,699	2,543	2,627
Total Long-Term Debt	0.00	1,395	2,670	2,671	2,772	2,778	2,653	2,486	2,219	2,620
Net Debt	0.00	1,407	2,473	2,539	2,470	2,552	2,707	2,600	2,424	2,316
Capital Expenditures (CapEx)	123	95	58	47	62	51	49	47	60	97
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	487	536	528	573	617	714	645	664	725
Debt-free Net Working Capital (DFNWC)	0.00	565	755	681	920	873	749	744	782	1,036
Net Working Capital (NWC)	0.00	475	733	660	875	843	659	531	458	1,030
Net Nonoperating Expense (NNE)	68	73	188	429	-4.77	78	188	192	248	234
Net Nonoperating Obligations (NNO)	0.00	1,422	2,473	2,668	2,466	2,550	2,707	2,600	2,424	2,316
Total Depreciation and Amortization (D&A)	36	51	154	250	244	243	249	241	265	246
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.62	$0.07	($0.86)	($0.48)	($0.38)	$0.23
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	298.69M	299.23M	147.44M	148.92M	150.94M	176.14M	308.98M	313.37M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.61	$0.07	($0.86)	($0.48)	($0.38)	$0.22
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	298.69M	299.23M	148.91M	151.82M	150.94M	176.14M	308.98M	324.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.16)	($2.74)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	127.25M	132.11M	299.82M	301.54M	303.62M	307.01M	309.97M	314.63M
Normalized Net Operating Profit after Tax (NOPAT)	292	223	195	-97	78	125	134	157	243	366
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-

This table displays calculated financial ratios and metrics derived from Amneal Pharmaceuticals' official financial filings.

Metric	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	314,362,920.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.11
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Net Operating Profit after Tax (NOPAT)	80	82	9.94	-7.52	79	68	53	66	77	49	101
Return On Investment Capital (ROIC_SIMPLE)	-	-	0.37%	-	-	-	2.18%	2.81%	3.26%	1.95%	3.93%
Earnings before Interest and Taxes (EBIT)	81	74	17	-9.82	86	81	46	94	117	89	111
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	140	133	78	46	143	141	139	161	184	148	164
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	238	254	265	270	287	393	334	241	300	120	159
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,771	2,747	2,661	2,525	2,563	2,422	2,380	2,351	2,340	2,351	2,322
Increase / (Decrease) in Invested Capital	-158	-171	-255	-278	-208	-325	-281	-175	-223	-71	-58
Book Value per Share	$1.04	$1.08	$0.06	($0.21)	($0.19)	($0.30)	($0.35)	($0.42)	($0.36)	($0.35)	($0.23)
Tangible Book Value per Share	($4.24)	($4.08)	($4.79)	($4.96)	($4.78)	($4.76)	($4.64)	($4.58)	($4.34)	($4.12)	($3.91)
Total Capital	2,882	2,840	2,760	2,574	2,609	2,501	2,498	2,416	2,421	2,587	2,633
Total Debt	2,700	2,648	2,699	2,590	2,613	2,534	2,543	2,476	2,468	2,629	2,627
Total Long-Term Debt	2,549	2,542	2,486	2,378	2,178	2,170	2,219	2,154	2,146	2,622	2,620
Net Debt	2,590	2,561	2,600	2,544	2,569	2,460	2,424	2,417	2,396	2,393	2,316
Capital Expenditures (CapEx)	11	12	12	10	11	17	22	14	26	15	42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	686	715	645	712	763	709	664	697	727	748	725
Debt-free Net Working Capital (DFNWC)	795	802	744	758	807	783	782	756	799	984	1,036
Net Working Capital (NWC)	644	695	531	546	371	418	458	435	478	976	1,030
Net Nonoperating Expense (NNE)	50	57	103	74	62	56	74	41	41	31	51
Net Nonoperating Obligations (NNO)	2,588	2,556	2,600	2,542	2,567	2,456	2,424	2,410	2,386	2,393	2,316
Total Depreciation and Amortization (D&A)	60	60	62	56	57	60	93	67	67	59	53
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.11
Adjusted Weighted Average Basic Shares Outstanding	153.74M	154.22M	176.14M	307.28M	309.12M	309.65M	308.98M	311.05M	313.74M	314.17M	313.37M
Adjusted Diluted Earnings per Share	$0.08	$0.06	($0.57)	($0.30)	$0.02	$0.00	($0.10)	$0.04	$0.07	$0.01	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	154.89M	159.69M	176.14M	307.28M	318.96M	309.65M	308.98M	323.96M	322.36M	324.75M	324.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	306.31M	306.54M	307.01M	308.65M	309.54M	309.84M	309.97M	313.42M	314.08M	314.36M	314.63M
Normalized Net Operating Profit after Tax (NOPAT)	53	54	2.42	60	79	67	55	66	77	49	103
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-

Financials Breakdown Chart

Key Financial Trends

Amneal Pharmaceuticals (AMRX) delivered a solid Q4 2025 set of results with improving top-line growth and stronger cash generation. Here are the 10 most material takeaways based on the latest quarterly data.

Strong revenue growth in Q4 2025: Operating revenue rose to $814,319,000, up from $730,518,000 in Q4 2024 (roughly an 11% year-over-year increase).
Healthy gross margin: Q4 2025 gross profit was $297,190,000 on $814,319,000 revenue, yielding a gross margin of about 36.5%, a modest improvement versus the year-ago quarter.
Profitability returns in Q4 2025: Net income from continuing operations was $49,573,000 with basic EPS of $0.11 and diluted EPS of $0.10, marking a move back into positive quarterly profitability.
Solid operating cash flow and free cash flow: Net cash from continuing operating activities was $130,315,000 in Q4 2025, and free cash flow was about $87.1 million (OCF of $130.3M less capex of $43.2M).
Consistent 2025 quarterly revenue growth: Revenue progressed through the year: Q1 $695.4M, Q2 $724.5M, Q3 $784.5M, culminating in Q4 $814.3M, showing a steady uptrend.
Capex activity: Capital expenditures in Q4 2025 were $43.2M for property, plant & equipment, reflecting ongoing investment in capacity and efficiency.
Balance sheet leverage signals: In Q3 2025, total liabilities were $3,642,049,000 and total assets were $3,599,874,000, indicating high leverage and a tight asset base on that quarter.
Significant debt burden: Long-term debt stood at $2,566,500,000 in Q3 2025, with total liabilities around $3.64B, underscoring a heavy leverage load.
Equity concerns on some filings: Total Common Equity reported as negative in Q3 2025 (approximately -$109.46M) and overall negative equity readings appeared in that period, signaling substantial accumulated losses or restatements.
Cash outflow for investing activities in Q4 2025: Net cash from investing activities was negative $45.45M in Q4 2025, reflecting ongoing capital deployment but a cash outflow from investments.

05/06/26 04:19 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

When does Amneal Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Amneal Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

How has Amneal Pharmaceuticals' net income changed over the last 9 years?

Amneal Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $127.93 million in 2025, falling from $209.43 million in 2016. The previous period was -$73.88 million in 2024. Check out Amneal Pharmaceuticals' forecast to explore projected trends and price targets.

What is Amneal Pharmaceuticals' operating income?

Amneal Pharmaceuticals' total operating income in 2025 was $394.10 million, based on the following breakdown:

Total Gross Profit: $1.11 billion
Total Operating Expenses: $719.21 million

How has Amneal Pharmaceuticals' revenue changed over the last 9 years?

Over the last 9 years, Amneal Pharmaceuticals' total revenue changed from $1.02 billion in 2016 to $3.02 billion in 2025, a change of 196.5%.

How much debt does Amneal Pharmaceuticals have?

Amneal Pharmaceuticals' total liabilities were at $3.67 billion at the end of 2025, a 3.6% increase from 2024, and a 113.8% increase since 2017.

How much cash does Amneal Pharmaceuticals have?

In the past 8 years, Amneal Pharmaceuticals' cash and equivalents has ranged from $25.98 million in 2022 to $341.38 million in 2020, and is currently $282.03 million as of their latest financial filing in 2025.

How has Amneal Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Amneal Pharmaceuticals' book value per share changed from 0.00 in 2016 to -0.23 in 2025, a change of -22.5%.

Related Companies

Financial statements for NASDAQ:AMRX last updated on 3/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Financials

Annual Income Statements for Amneal Pharmaceuticals

Quarterly Income Statements for Amneal Pharmaceuticals

Annual Cash Flow Statements for Amneal Pharmaceuticals

Quarterly Cash Flow Statements for Amneal Pharmaceuticals

Annual Balance Sheets for Amneal Pharmaceuticals

Quarterly Balance Sheets for Amneal Pharmaceuticals

Annual Metrics And Ratios for Amneal Pharmaceuticals

Quarterly Metrics And Ratios for Amneal Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Amneal Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools